Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
2.240
-0.030 (-1.32%)
At close: Jan 30, 2026, 4:00 PM EST
2.220
-0.020 (-0.89%)
Pre-market: Feb 2, 2026, 4:01 AM EST
Clover Health Investments Stock Forecast
Stock Price Forecast
The 2 analysts that cover Clover Health Investments stock have a consensus rating of "Buy" and an average price target of $3.35, which forecasts a 49.55% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $3.70.
Price Target: $3.35 (+49.55%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Clover Health Investments stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $3.7 | Strong Buy | Maintains | $3.7 | +65.18% | Jan 20, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.1 → $3.7 | Strong Buy | Maintains | $4.1 → $3.7 | +65.18% | Nov 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.5 → $4.1 | Strong Buy | Maintains | $4.5 → $4.1 | +83.04% | Aug 7, 2025 |
| UBS | UBS | Hold Maintains $4.5 → $3 | Hold | Maintains | $4.5 → $3 | +33.93% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +100.89% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
1.94B
from 1.37B
Increased by 41.68%
Revenue Next Year
2.80B
from 1.94B
Increased by 43.92%
EPS This Year
-0.18
from -0.09
EPS Next Year
-0.03
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.0B | 3.0B | ||||
| Avg | 1.9B | 2.8B | ||||
| Low | 1.9B | 2.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 46.4% | 55.6% | ||||
| Avg | 41.7% | 43.9% | ||||
| Low | 35.2% | 32.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | 0.02 | |||
| Avg | -0.18 | -0.03 | |||
| Low | -0.18 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.